|
Match
|
Document |
Document Title |
|
|
US20090317470 |
Oramucosal Pharmaceutical Dosage Form
This invention relates to an oramucosal pharmaceutical dosage form in the form of a wafer. The wafer comprises a porous, hydroscopic, muco-adhesive polymeric matrix with at least one desired...
|
|
|
US20090318491 |
Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders
The present invention relates to compounds which are derivatives of cytisine or acetylcholine which exhibit activity as agonists, partial agonists or antagonists of nicotinic acetylcholine...
|
|
|
US20090304826 |
Method and composition for dermatoses
The invention provides a method and composition for treating dermatoses by topical application of a composition containing an antihistamine, an NSAID and optionally a botanical medicinal compound....
|
|
|
US20090274656 |
HEPATITIS C VIRUS INHIBITORS
Hepatitis C virus inhibitors are disclosed having the general formula:
wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds...
|
|
|
US20090270414 |
2,3,4,9- TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects...
|
|
|
US20090270440 |
BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS
The invention relates to the use of N,N′-dihydroxyamidine (I), N,N′-dihydroxyamidine ether (II), N,N′-dihydroxyamidine diether (III), N,N′-dihydroxyamidine ester (IV),...
|
|
|
US20090258852 |
Inhibitors of Checkpoint Kinases
The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such...
|
|
|
US20090238760 |
ANTISPERMATOGENIC, SPERMICIDAL AND/OR ANTIFUNGAL COMPOSITION AND METHODS OF USING THE SAME
Hexahydroindenopyridine compounds are disclosed which act as contraceptive agents by disrupting spermatogenesis, acting as spermicides or sperm motility inhibitors and/or act as antifungals;...
|
|
|
US20090221624 |
4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS
This invention is directed to aminoquinoline compounds, pharmaceutical compositions of such compounds, kits comprising such compounds, and uses of such compounds for preparing medicaments and...
|
|
|
US20090215811 |
Novel Pharmaceutical Composition and Its Use in a Method For Treatment of Patients With Upper Respiratory Mucosal Congestion
The present invention relates to a pharmaceutical composition including loratidine, its use in the treatment of upper respiratory mucosal congestion and a method of administration of the...
|
|
|
US20090203684 |
Tyrosine kinase inhibitors
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated...
|
|
|
US20090203727 |
NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION
The present invention relates to a pharmaceutical composition including loratadine or a pharmaceutically acceptable form thereof, and phenylephrine or a pharmaceutically acceptable form thereof,...
|
|
|
US20090203726 |
SUBSTITUTED TETRAHYDROQUINOLINES AS ANTIBACTERIAL AGENTS
A method of treating a subject for a bacterial infection includes administering to a subject in need of treatment for a bacterial infection an effective amount of a compound represented by...
|
|
|
US20090197907 |
NOVEL CRYSTALLINE FORM OF RUPATADINE FREE BASE
The present invention relates to a novel crystalline form of rupatadine free base, process for its preparation and to a pharmaceutical composition containing it. In accordance with the present...
|
|
|
US20090197908 |
Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity,...
|
|
|
US20090182002 |
Tyrosine kinase inhibitors
This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl- 1 H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-
7-yl]sulfamide, an...
|
|
|
US20090176804 |
2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient...
|
|
|
US20090156469 |
METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF IN TREATING WALDENSTROM'S MACROGLOBULINEMIA
Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.
|
|
|
US20090148543 |
Method for protecting humans against superficial vasodilator flush syndrome,
Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides...
|
|
|
US20090137620 |
USE OF GALLIUM(III) COMPLEXES FOR THE TREATMENT OF MELANOMAS
The invention relates to the use of gallium (III) complexes for the treatment of melanomas.
|
|
|
US20090137558 |
Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products
The present invention relates to substituted pyridine compounds of Formula (I) and derivatives thereof, and to a process for preparing these substituted pyridines. The invention also relates to the...
|
|
|
US20090131412 |
NOVEL 2-QUINOLONE DERIVATIVE
A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof which has a therapeutic or prophylactic effect on an SNS-related disease such as neuropathic pain. (1)...
|
|
|
US20090124651 |
CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF
The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.
|
|
|
US20090118267 |
INDANES
Compounds of the formula (I), in which R 1 , R 2 , R 3 , R 4 , and q have the meanings indicated in claim 1 , can be employed, inter alia, for the treatment of tumours.
|
|
|
US20090105240 |
Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates...
|
|
|
US20090082385 |
DEUTERIUM-ENRICHED DESLORATIDINE
The present application describes deuterium-enriched desloratadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090081314 |
Glycemic Control, Diabetes Treatment, and Other Treatments with Acetyl Cholinesterase Inhibitors
There is disclosed a method for glycemic control of a patient having a disease selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance,...
|
|
|
US20090053290 |
TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN
Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically...
|
|
|
US20090036387 |
NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS
Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that...
|
|
|
US20090029949 |
GPCR Ligands Identified by Computational Modeling
Disclosed are pharmacophores for developing and screening compounds having G-protein-coupled receptor antagonist activity, including LPA 1 , LPA 2 , LPA 3 and S1P antagonists. These compositions...
|
|
|
US20090012074 |
Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor
The present invention relates to aromatic compounds of the formula I
wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and...
|
|
|
US20090005362 |
Compositions Comprising Antihistamines or Mast Cell Stabilizers, and Methods of Making and Using Same
Compositions comprise: (a) a material selected from the group consisting of antihistamines, stabilizers, salts thereof, and combinations thereof; and (b) a vasoconstrictor, decongestant, or a salt...
|
|
|
US20080318996 |
6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R...
|
|
|
US20080317853 |
Mouth Dissolving Pharmaceutical Composition and Process for Preparing the Same
Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of...
|
|
|
US20080293693 |
Treatment or Prevention of Ovarian Hyperstimulation Syndrome (Ohss) Using a Dopamine Agonist
Disclosed herein is a method for preventing ovarian hyperstimulation syndrome in a subject by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. Also...
|
|
|
US20080287481 |
PROCESS FOR THE PREPARATION OF DESLORATADINE POLYMORPH MIXTURES
The present application provides a process for the preparation of mixture of polymorphic Form I and Form II of desloratadine in any desired ratio.
|
|
|
US20080280938 |
Screening Method
The present invention provides a medicament for preventing/treating cancer, comprising a tacrine compound, or a compound promoting the binding between the tacrine compound and a protein comprising...
|
|
|
US20080269273 |
TREATMENT METHOD
Methods of treating and/or preventing a cardiovascular disease in a human suffering from an allergic and/or inflammatory condition or cardiovascular disease by administrating an effective amount of...
|
|
|
US20080262017 |
Sugar-Free Storage-Stable Antihistaminic Syrups
New and improved storage-stable sugar-free antihistaminic syrups are disclosed.
|
|
|
US20080261953 |
Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are...
|
|
|
US20080260837 |
Physically stable aqueous suspensions of active pharmaceuticals
The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides...
|
|
|
US20080248035 |
Pharmaceutical Combination
This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents,...
|
|
|
US20080242657 |
Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as...
|
|
|
US20080221118 |
Tetrahydroquinoline Derivatives
Compounds of the formula I, in which s, k, I, W, R 1 , R 2 , R 3 , and U have the meanings indicated in claim 1 , can be employed, inter alia, for the treatment of tumours.
|
|
|
US20080220003 |
C5a Receptor Antagonists
The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17,...
|
|
|
US20080207530 |
Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an...
|
|
|
US20080207537 |
Topical Ungual Formulations
Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.
|
|
|
US20080207593 |
Antihistamine Combination
A once daily formulation containing the combination of a non-sedating or selective antihistamine (Loratadine) with a sedating or non-selective antihistamine (Chlorpheniramine) administered at...
|
|
|
US20080194532 |
Compositions containing quaternary ammonium compounds
Compositions containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, where composition includes at least 20%...
|
|
|
US20080188462 |
Quinoline Derivatives And Uses Thereof
This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQ R and CQ S malaria parasites. RCQs are hybrid molecules,...
|